use in the 20 ml of solvent provided to give a solution of 1.5 mg per ml. It contains no bacteriostatics. Etomidate has no analgesic properties and should therefore be followed by other anaesthetic agents for the maintenance of anaesthesia. Etomidate was first used clinically in 1972 by Doenicke 2 after experimental investigations in rats by Janssen, et al. 1 On the basis of their reports, we felt justified to carry out this preliminary study on our patients.
METHOD
A total of 32 patients were studied. They were undergoing different minor surgical procedures as listed in Table I. C.E. Famewo, M.B., B.S., Dip.Anaes., F.R. 
Dose Schedule
The dose of etomidate used for this study was 0.3 mg/kg body weight. This was chosen as the optimum sleep dose after smaller dose schedules had failed to give satisfactory conditions at induction.
Premedication
Seventeen of the 32 patients received atropine and meperidine (pethidine) premedication by intramuscular injection on the ward about 45 minutes before induction. The remaining 15 patients received no premedication on the ward but were given atropine intravenously a few minutes before induction.
Induction of anaesthesia
Base line blood pressure, pulse and respiratory rate were taken. Etomidate in a dose of 0.3 mg/kg was injected intravenously over about 20 seconds. Following etomidate iniection , the following observations were made:
1. Time to loss of consciousness from end of injection. 2. Pulse rate and blood pressure. 3. Respiratory rate and depth of respiration.
Maintenance of anaesthesia
Nitrous oxide and oxygen in the ratio of 2 to 1 and halothane were administered by face-mask after the post-etomidate readings of the pulse rate, blood pressure and respiration rate had been taken.
RESULTS
Etomidate in the dose used gave smooth and fast induction of anaesthesia in all but two patients that had market myoclonic movements.
Time to loss of consciousness
The average time to loss of consciousness (as determined by fall of the outstretched arm from the end of iniection) was 15,7 sec in the premedicated group and 18.2 sec in the unpremedicated group. Pain Nine patients (five premedicated and four unpremedicated) complained of pain during the intravenous injection of etomidate, being an incidence of 28 per cent. The pain disappeared oll flushing with water for injection. Seven out of these nine patients had the injection site on the dorsum of the hand.
Myoclonic movements
Twelve patients (37.5 per cent) had myoclonic movements during induction. 'These were generally mild and self-limiting except in two patients (6.25 per cent) where diazepam had to be given to terminate them.
Cardiovascular system
There was a tendency towards a small increase in the pulse rate and blood pressure following etomidate injection. However, these increases were statistically not significant (Table II ) .
Respiratory system
From clinical observation, respiratory rate and depth were fairly well sustained after etomidate injection except in the two patients with severe myoclonic movements, one of whom had a short period of apnoea which did not require assisted ventilation.
DISCUSSION
Etomidate offers some advantages as an agent for induction of anaesthesia. Induction was usually fast and smooth. We were particularly impressed that the heart rate and blood pressure were not significantly changed after etomidate injection. This is an important advantage over thiopentone, especially in patients with labile cardiovascular systems. Our findings are similar to those of Doenicke, 3 et al. and more recently Gooding and Corssen. 4 The two undesirable side-effects we have found so far are the rather frequent occurrence of myoclonic or involuntary movements as well as pain on injection of the drug in some of the patients. Further work is in progress to find ways and means of overcoming these side effects. Based on our present preliminary experience, etomidate looks promising and further clinical investigations are desirable. This is a preliminary report of our clinical experience with etomidate, a new intravenous non-barbiturate anaesthetic agent. Thirty-two patients undergoing minor surgical procedures were anaesthetized, induction being with etomidate 0.3 mg/kg body weight. Induction was fast and smooth. Twenty-eight per cent of the patients complained of pain at site of injection but the pain disappeared on flushing with water for injection. Following etomidate injection, 37.5 per cent of patients developed myoclonic movements which were usually mild and self-limiting. We were impressed by the relative stability of the cardiovascular and respiratory systems. Etomidate looks promising and further work is in progress on other aspects of this drug.
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Rtsu~
Les auteurs rapportent leurs premieres impressions cliniques de l'etomidate, un nouvel anesthtsique intraveineux non barbiturique. L'etomidate a 6t6 utilis6 cornme agent d'induction chez 32 malades devant subir une chirurgie mineure. La dose utiliste a 6t6 de 0.3 mg/kilo. L'induction 6tait rapide et facile. Ving-huit pour cent des patients se sont plaints de douleur au site d'injection, douleur qui disparaissait lorsque l'on irriguait la veine. Trente-sept pour cent des patients ont pr6sent6 des mouvements cloniques ltgers, mouvements qui cessaient d'eux-m~mes gtntralement. Nous avons 6t6 impressionnts par la stabilit6 des param~tres cardiovaseulaires et respiratoires.
C'est un agent qui nous apparait prometteur et nous poursuivons notre 6tude.
